Acquisition pipeline puts Novanta (NOVT) in focus

Novanta (NOVT) has moved into the spotlight after outlining an active acquisition pipeline supported by a robust balance sheet and an expanded credit facility, which gives the company more flexibility to pursue recurring, software-driven revenue opportunities.

The acquisition update lands after a strong run in the stock, with a 30-day share price return of 27.83% and year-to-date share price return of 47.08%. The 1-year total shareholder return of 34.07% contrasts with a flat 3-year total shareholder return, suggesting momentum has recently picked up.

If this kind of momentum has your attention, it could be a moment to scan for other robotics and automation opportunities using the 33 robotics and automation stocks.

With Novanta trading close to analyst price targets after a sharp run and carrying an intrinsic value estimate at a premium to today’s US$163.46 share price, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?

Preferred P/E of 108.4x: Is it justified?

On a P/E of 108.4x, Novanta’s $163.46 share price sits well above both peer and internal fair value benchmarks that cluster around roughly half that level.

The P/E ratio compares the current share price with earnings per share, so a higher multiple usually reflects higher expectations for future profitability or perceived quality. For a company exposed to precision medicine, medical solutions, and automation, investors often focus on how durable and scalable those earnings streams might be.

Here, the gap is wide. Novanta’s P/E of 108.4x stands above the peer average of 67.9x and also above the estimated fair P/E of 49.1x, suggesting the market is paying a premium multiple that is well ahead of where valuation models indicate it could settle.

Result: Price-to-Earnings of 108.4x (OVERVALUED)

However, the stretched P/E ratio and a 56% premium to intrinsic value estimates leave little margin for error if acquisition plans or earnings trends disappoint.

Another angle on value

While the 108.4x P/E points to a rich price, the SWS DCF model also suggests Novanta is not cheap, with an estimated fair value of $104.93 versus the current $163.46. Both methods lean the same way, so the real question is what could justify paying this kind of premium.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Novanta for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this combination of strong recent returns and what appears to be a full valuation feels finely balanced, it may be helpful to review the data now and decide where you stand using the 1 key reward and 1 important warning sign.

Looking for more investment ideas?

If Novanta has sparked your interest, do not stop here. Broaden your watchlist with other stocks that match clear, data driven criteria across value, quality, and income.

• Target potential bargains by scanning 47 high quality undervalued stocks that align with solid fundamentals and attractive valuations.
• Strengthen your downside protection by reviewing the 62 resilient stocks with low risk scores and focusing on companies with more resilient profiles.
• Boost your income shortlist by checking the 10 dividend fortresses that combine higher yields with staying power.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.